Navigation Links
Oncothyreon reports full year and fourth quarter 2008 financial results
Date:3/9/2009

from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Additional Information

Additional information relating to Oncothyreon can be found on U.S. EDGAR at www.sec.gov and on SEDAR at www.sedar.com.

                              Oncothyreon Inc.

    Consolidated Statements of Operations and Other Comprehensive Income
                                 (Loss) Data
          (in thousands of U.S. dollars, except per share amounts)
                                 (unaudited)


                                    Three Months Ended   Twelve Months Ended
                                        December 31          December 31
                                   --------------------  --------------------
                                       2008       2007       2008       2007
                                   ---------  ---------  ---------  ---------
    Revenue
      Contract research and
       development..............   $      -   $     29   $      -   $    631
      Contract manufacturing....     12,636      1,617     15,582      2,536
      Licensing revenue from
       collaborative
       agreements......
'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
2. Oncothyreon to present at BIO CEO & Investor Conference 2009
3. Oncothyreon reports third quarter 2008 financial results
4. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
5. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
6. Oncothyreon to present at BIO Investor Forum 2008
7. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
8. Oncothyreon announces prioritization plan for development programs
9. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
10. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
11. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a leader in ... is to open in Manhattan, Kansas in early October, 2015. The location of ... research and development through collaboration with researchers from Kansas State University’s College of ...
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
(Date:8/26/2015)... 26, 2015 Intrexon Corporation (NYSE: XON ... closing of its previously announced public offering of common ... of their option to purchase an additional 731,707 shares ... $41.00 per share.  The exercise of the underwriters, option ... sold by Intrexon to 5,609,756 shares and increased the ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... CRTX ), a specialty pharmaceutical company focused on acquiring, developing and ... for the year ended December 31, 2008. Highlights: , ... Net Revenues more than doubled to $64.9 Million, an increase of 131% ... , Income from Operations increased to ...
... natural skin care product called Ambra-Lift™ by Elina™ Organics ... a substance found in the skin of grapes and red wine, has ... Resveratrol. , ... Kalamazoo, MI (PRWEB) March 26, 2009 -- A recent ...
... 25 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... outsourcing company serving the,pharmaceutical, biotechnology, and medical device ... today announced its financial results for,fourth-quarter and full-year ... ), Highlights, ...
Cached Biology Technology:Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 2Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 3Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 4Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 5Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 6Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 7Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 8Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 9Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 10Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 11Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 12Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 2Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 3Genomic Study Shows Organic Skin Care Product Activates Key Anti-Aging Gene 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results 20
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
(Date:8/10/2015)... 10, 2015 The latest 364 page ... analysis of the global border security market . ... $16.4bn in 2015. Now: Border security is hard ... of the business critical issue you need to know about ... ,s objective analysis of how this will impact your company ...
(Date:8/6/2015)... and TELTOW, Germany , August 6, ... Conference, SensoMotoric Instruments (SMI) shows the world,s ... , based on Epson,s Moverio BT-200 see-through head ... With this new solution, unprecedented quality and efficiency is ... with context-sensitive displays. For the first time, professionals and ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... The Brain-Computer Interface (BCI) research team at Singapore,s ... the worldwide BCI Competition IV, 2008, in all ... The results were announced on Dec. 12 ... conference in Vancouver, Canada. The Singapore scientists ...
... COLD SPRING HARBOR, N.Y. (Dec. 18, 2008) ... . They build, process, activate, and inactivate; they polymerize, ... shorten, signal, cleave, inhibit, digest, fluoresce, induce, excise, carry, ... and perform countless more activities." This excerpt is ...
... of pregnancy is clearly linked with an increased risk of cleft ... cigarette smoke do not appear to be involved. This is shown ... Oral clefts are one of the most common birth ... followed by closure of the palate at week 9. If this ...
Cached Biology News:Singapore research team first place in Brain-Computer Interface contest 2New manual presents robust, state-of-the-art proteomics methods for teaching and research 2First trimester smoking linked to oral clefts 2
A flexible 24-48 hour DNA sequencing service. Samples may be shipped in standard 1.5mL tubes. Oligo synthesis and DNA preparation available. Read lengths up to 850 Phred 20 bases. Universal primers p...
... Agencourt offers single pass sequencing ... service is fueled by our high ... 20 million Phred20 bases per day. ... single pass sequencing customers are rapid ...
... Facility , Galaxy LIMS, Sophisticated Bioinformatics , ... scientists ,We offer individual sample sequencing of ... for single or double strand publication quality. ... DNA of interest is 1.3 to 7 ...
... Agencourt offers quick turnaround sequencing of ... copy and high copy plasmids. Agencourt's world-class, ... million Phred20 bases per day. The ... Sequencing service are 24 48 hour ...
Biology Products: